Latest Stock Research & Market Analysis
Search All Research, Articles & Stock Profiles
ASX Stock Research
[BUY] ResMed (ASX: RMD) – Growth Levers in Place for a Re-Rate
Buy ResMed at A$26.68 with a A$46.70 target and 75% upside. The GLP-1 fear is fading, new growth levers are scaling, and it trades below medtech peers.
[BUY] Collins Foods (ASX: CKF) – Qld and WA Exposure Outweighs the Wage Cost Squeeze
Collins Foods (ASX: CKF) at A$8.27 trades ~20% below its historical PE. Qld/WA exposure plus a kiosk rollout offset wage pressure. 29% upside, Buy.
[BUY] WEB Travel Group (ASX: WEB): Near-Term Headwinds Create a Value Entry Point
Institutional sell-side rates WEB Travel Group a Buy with a 12-month price target of A$4.70. The stock closed at A$2.23 on 20 May 2026, implying roughly 111 per cent upside to that target. The bull case rests on three pillars: the hotel bed wholesaling sector is...
[BUY] WEB Travel Group (ASX: WEB): Near-Term Headwinds Create a Value Entry Point
Institutional sell-side rates WEB Travel Group a Buy with a 12-month price target of A$4.70. The stock closed at A$2.23 on 20 May 2026, implying roughly 111 per cent upside to...
[BUY] Nick Scali (ASX: NCK): Margins, Growth and a Franked Yield
Institutional sell-side rates Nick Scali a Buy with a 12-month price target of around A$20. The stock closed at approximately A$14.47 on 9 May 2026, implying roughly 38 per cent...
Global Marco and Market Research
The Australian Consumer Was Already Last in the G10 on Spending. The RBA Hiked Anyway.
The G10 consumer dashboard puts Australian household spending growth dead last in the developed-market cohort. Tuesday’s RBA hike to 4.35 percent continues the squeeze. What that means for a domestic portfolio.
The Q1 CPI Was Mixed. The RBA Still Has to Hike on Tuesday.
The Reserve Bank Board meets on Monday and Tuesday next week with a rate decision at 2:30pm AEST on Tuesday. This is the most anticipated single-meeting call we have had in nine months. The case rests on a Q1 CPI print released on Wednesday that did two things at...
Why the Iran Oil Shock Points to More RBA Hikes, Not Fewer
The default narrative around the Iran conflict and the oil spike that has followed it is that it is bad news, full stop. Higher energy costs feed into inflation, dent consumer spending, and put pressure on central banks to either hold tight or cut rates to cushion the...
Global Stock Research
[BUY] MongoDB (MDB): The AI Data Layer Play With a Clear Path to $4bn Revenue
MongoDB (MDB) is rated a Buy with a US$360 price target, implying 8 per cent upside. The thesis rests on Atlas cloud consumption growth, an AI-native product strategy, and an earnings trajectory that compresses the P/E from 55x to 36x by FY29.
[BUY] Upwork (NASDAQ: UPWK) – Restructuring Sharpens the Margin Story
Upwork delivered a Q1'26 result that landed on the right side of a bifurcated narrative. Revenues came in around the midpoint of guidance at $195mn, while Adj. EBITDA of $57mn came in nearly 24% above consensus expectations, with the margin beat tracing back to a cost...
[BUY] Eli Lilly (LLY): Foundayo Reframes the Oral GLP-1 Story
LLY Buy with ~37% upside to ~US$1,283. 1Q26 EPS US$8.55 beat US$6.77, 2026 guide raised to US$82-85bn. Foundayo oral GLP-1 hits 8k prescribers in 3 weeks, 80% new incretin patients.
[BUY] Eli Lilly (LLY): Foundayo Reframes the Oral GLP-1 Story
LLY Buy with ~37% upside to ~US$1,283. 1Q26 EPS US$8.55 beat US$6.77, 2026 guide raised to US$82-85bn. Foundayo oral GLP-1 hits 8k prescribers in 3 weeks, 80% new incretin patients.
[HOLD] Tesla (NASDAQ: TSLA) A Strong Q1 But No Free Cash Flow Until 2028
Tesla (NASDAQ: TSLA) A Strong Q1 But No Free Cash Flow Until 2028 Tesla just delivered a first quarter result that was stronger than the market expected, with revenue beating the...
Region & Industry Outlook
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
ASX Announcement
Orezone Gold Corporation (ASX: ORE) – Q2 2026 Casa Berardi Production Update
Orezone Gold Corporation has delivered its first full quarter as a multi-mine producer, with both the Bomboré and Casa Berardi operations meeting expectations in Q2 2026 following the acquisition of Casa Berardi in March. The company produced 38,789 ounces of gold...
Janus Henderson Group plc (ASX: JHG) – Janus Henderson Files Distribution Payment 2
JPMorgan Asset Management has announced updated distribution amounts for its two Global Equity Premium Income Complex ETFs, with the JPMorgan Global Equity Premium Income Complex ETF (JEGA) to distribute 28.0988 cents per unit and the hedged version (JHGA) to...
Steadfast Group (ASX: SDF) – Further update on indicative proposal
Steadfast Group has received a significant development in its takeover process, with Kohlberg Kravis Roberts (KKR) joining the consortium pursuing the insurance broker. The move strengthens the financial backing behind the proposed $6.00 per share acquisition, though...
Steadfast Group (ASX: SDF) – Further update on indicative proposal
Steadfast Group has received a significant development in its takeover process, with Kohlberg Kravis Roberts (KKR) joining the consortium pursuing the insurance broker. The move...
Mesoblast (ASX: MSB) – Phase 3 CLBP Trial Reaches 300 Patients
Mesoblast Limited has achieved a significant milestone in its development of a treatment for chronic low back pain, announcing that it has treated its target of 300 patients in...
Top Stock Reports
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Subscribe
Want more Free Research?
Subscribe today for free and get an alert when we have new research and webinars.
MF & Co. Asset Management
MF & Co. Asset Management is a boutique investment firm offering Equity Capital Markets and derivative general advice & trade execution services.
We are specialists in advising and trading in Australian and US Equities, Index & Equity Options and Options on Futures.
Contact
Get In Touch
Australia
1300 889 603
International
+61 2 8378 7199
M-F: 8am-5pm
Suite 803, Level 8
70 Pitt St, Sydney, NSW 2000